Given the importance of the FGF-2/KDM2B-EZH2/miR-101/EZH2 axis in bladder cancer, we hypothesize that there will be clinical utility to the therapeutic targeting of this pathway. Here, KDM2B is linked to urinary bladder carcinoma.